Treatment of neurofibromatosis 1-associated malignant peripheral nerve sheath tumors: a systematic review
- 109 Downloads
Malignant peripheral nerve sheath tumors (MPNST) are a rare and aggressive group of tumors that are challenging to treat. Neurofibromatosis type 1 (NF-1)-associated MPNSTs have been associated with poorer clinical outcomes. The treatment options for NF-1-associated MPNSTs broadly include surgery (SG), chemotherapy (CT), and adjuvant radiotherapy (RT). Overall, the role and efficacy of CT and RT are unclear. Examination of existing literature for studies reporting on NF-1-associated MPNSTs and respective treatment-related outcomes was conducted. We conducted a systematic review according to PRISMA guidelines in PubMed/Medline and Cochrane databases of studies which reported treatment-specific outcomes in NF-1-associated MPNSTs. The literature search found 444 records after removal of duplicates. The present study included 50 patients across 12 observational studies. All of the included studies reported data on overall survival (OS 52%, n = 26/50) but mean follow-up in months among the studies and among patients varied widely, between 10.85 (SD, ± 10.38) and 192 (SD, ± 98.22). From the included studies, patients underwent either SG alone (n = 21), SG + CT (n = 10), SG + RT (n = 7), or SG + CT + RT (n = 12). The quality of evidence in the literature regarding optimal treatment options for NF-1-associated MPNSTs remains tenuous. Future retrospective and prospective comparative trials should consider adherence to a set of reporting guidelines to improve the quality of evidence in the literature with respect to individual treatment-related outcomes. The need for prospective multi-institutional efforts cannot be overstated.
KeywordsMalignant peripheral nerve sheath tumor MPNST Neurofibromatosis 1 NF-1 Publishing guidelines Chemotherapy Radiotherapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Not applicable for this systematic review.
Not applicable for this systematic review.
- 7.Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107(5):1065–1074CrossRefGoogle Scholar
- 9.Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62(5):1573–1577Google Scholar
- 12.Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, Fatyga A, Budka A, Balwierz W, Sobol G, Zalewska-Szewczyk B, Rychlowska-Pruszynska M, Klepacka T, Dembowska-Baginska B, Kazanowska B, Gabrych A, Bien E (2018) Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol 144(3):519–529CrossRefGoogle Scholar
- 16.Alina B, Sebastian JA, Gerardo C (2015) Malignant triton tumors in sisters with clinical neurofibromatosis type 1. Case Rep Oncol Med 2015:405351Google Scholar
- 19.del Carmen Baena-Ocampo L, Reyes-Sanchez A, Alpizar-Aguirre A, Rosales-Olivares LM (2009) Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: report of two clinical cases. Cir Cir 77(5):391–395Google Scholar
- 23.Asavamongkolkul A, Jiranantakan T, Waikakul S, Phompitaksa K, Muangsomboon S (2001) Malignant peripheral nerve sheath tumor with neurofibromatosis type 1: a 2-case report and review of the literature. J Med Assoc Thail 84(2):285–293Google Scholar
- 24.Chang SM, Ho WL (1994) Malignant peripheral nerve sheath tumor: a study of 21 cases. Zhonghua Yi Xue Za Zhi (Taipei) 54(2):122–130Google Scholar
- 28.Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27(19):3133–3140CrossRefGoogle Scholar
- 29.Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH (2009) Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 27(19):3148–3153CrossRefGoogle Scholar
- 30.Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH (2016) SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6):868–874CrossRefGoogle Scholar
- 31.Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, de Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23(33):8422–8430CrossRefGoogle Scholar
- 32.Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1):197–203CrossRefGoogle Scholar